Scholar Rock Holding Corporatio (SRRK) Stock Analysis

Scholar Rock's lead candidate, apitegromab—the first selective latent myostatin inhibitor to achieve a statistically significant Phase 3 outcome in spinal muscular atrophy—reported positive SAPPHIRE trial results in October 2024. The company submitted a BLA to the FDA in January 2025 and a marketing authorization application to the EMA in March 2025. Scholar Rock received a Complete Response Letter from the FDA in September 2025 citing GMP deficiencies at a third-party fill-finish facility, delaying the anticipated U.S. commercial launch.

Scholar Rock plans to commercialize apitegromab for SMA, subject to regulatory approval, targeting initial launches in the U.S. and Europe beginning with Germany, supported by a U.S. customer-facing team of approximately 50 neurology and rare disease professionals established during 2025. An estimated 35,000 SMA patients globally have received an approved SMN-targeted treatment, defining the initial addressable market for apitegromab as a muscle-targeted complement. The company relies on a third-party fill-finish facility for apitegromab commercial manufacturing—the same facility that received an FDA Form 483 in July 2025 and an FDA warning letter in November 2025, with an OAI inspection classification that prompted the BLA's CRL. A subcutaneous formulation of apitegromab completed a Phase 1 healthy volunteer study; further development activities are ongoing. SRK-439, a subcutaneously administered anti-myostatin antibody in Phase 1, has topline data expected in the second half of 2026.